{
  "pmcid": "6031280",
  "sha256": "213488d6cf946f36bf4d608f851d3da83138a6496dcf5fe10853f4e345356add",
  "timestamp_utc": "2025-11-10T00:00:21.776331+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.567727272727272,
    "reading_ease": 34.346590909090935,
    "word_count": 264
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Caudal Zona Incerta Deep Brain Stimulation in Parkinson’s Disease"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In a single-blind, randomised controlled trial, 25 patients with idiopathic PD, eligible for subthalamic nucleus DBS, were randomised to either bilateral cZi DBS or best medical treatment."
      },
      "Participants": {
        "score": 2,
        "evidence": "25 patients with idiopathic PD, eligible for subthalamic nucleus DBS"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to either bilateral cZi DBS or best medical treatment"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to objectively evaluate the efficacy of deep brain stimulation (DBS) in the caudal zona incerta (cZi) for treating Parkinson’s disease (PD) symptoms."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcomes were differences in the motor scores of the Unified Parkinson’s Disease Rating Scale (UPDRS-III) and the Parkinson’s Disease Questionnaire 39 items (PDQ-39) at 6 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "25 patients with idiopathic PD"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Nineteen patients completed the study: 9 in the DBS group and 10 in the medical group."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The DBS group showed a 41% improvement in UPDRS-III scores off-medication on-stimulation compared to baseline, while the medical group showed no change."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events included one case of deep venous thrombosis in the DBS group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not specified."
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}